Xcout Intel
Petros Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Petros Pharmaceuticals, Inc. among pharmaceuticals companies — ranked by similarity to what Petros Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Petros Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Petros Pharmaceuticals, Inc. at a glance
Petros Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in New York City, United States. It is publicly listed (PTPI) with a market capitalisation of $169,489. Xcout tracks 11 named people at Petros Pharmaceuticals, Inc., including Fady Boctor (President & Chief Commercial Officer).
Petros Pharmaceuticals, Inc. leadership
- Fady BoctorPresident & Chief Commercial Officer
- Robert WeinsteinChief Accounting Officer, Principal Financial Officer & Principal Accounting Officer
- Joshua N. SilvermanExecutive Chairman of the Board
- Mitch ArnoldVP of Finance, Chief Accounting Officer
- Josh SilvermanVice-Chairman of the Board
- Bruce BernsteinDirector
5 more named people on record for Petros Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Petros Pharmaceuticals, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $125,000 | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Petros Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Petros Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Panther Life Sciences is a privately held biotechnology company founded in 2023 and headquartered in New York, NY. The company licenses and develops new treatments utilizing dissolvable microarray patch (MAP) technology to deliver shelf-stable medicine through the skin.
Similar pharmaceuticals company
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
Similar pharmaceuticals company
Pacira BioSciences, Inc. is a pharmaceutical company headquartered in Brisbane, California, focused on transforming how the world treats pain.
Biotechnology
Eyenovia, Inc. is a New York-based ophthalmic technology and pharmaceutical manufacturing company focused on targeted drug-delivery solutions for eye care using its proprietary Optejet device.
Biotechnology
Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.
Healthcare Services
Longevity Health Holdings Inc. specializes in creating plasma-based bioactive materials (PBMs) aimed at fostering tissue regeneration and repair in response to injury, illness, and the natural aging process. The company's primary investigational product is CT-101, which acts as a powerful accelerant for bone healing in diverse applications such as tibia fracture recovery, foot/ankle and spinal fusions, serving as a dental bone graft substitute, and filling bone voids. Additionally, CT-101 functions as a tissue healing accelerant, offering potential for treating androgenetic alopecia and persistent chronic wounds. Established in 2008, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Biotechnology & Pharmaceuticals
Marius Pharmaceuticals, LLC develops hormone health therapies focused on testosterone deficiency and metabolic vitality. The company offers KYZATREX, an oral prescription drug used to treat adult men with low or no testosterone levels due to specific medical conditions.
Similar pharmaceuticals company
Clarus Therapeutics is a U.S. specialty pharmaceutical company focused on men’s health and testosterone replacement therapy. It developed JATENZO (testosterone undecanoate), an oral testosterone replacement treatment for adult men with hypogonadism associated with a medical condition.
Similar pharmaceuticals company
Endo Medical provides pharmaceutical products and scientific medical information resources for healthcare professionals in the United States. The company distributes medications spanning various therapeutic areas, including endocrinology, urology, pain management, and specialized therapies, while offering tools to submit medical inquiries and report adverse events.
Similar pharmaceuticals company
Harrow Health, Inc. is a specialty pharmaceutical company focused on ophthalmic products, including FDA-approved and compounded medications used in eye care. It serves ophthalmologists, other eye-care professionals, and patients requiring treatments for conditions and procedures involving the eye.
Similar pharmaceuticals company
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Similar pharmaceuticals company
Helus Pharma Inc. advances mental health treatments by developing novel, second-generation therapies, proprietary drug delivery systems, and patent-protected molecules. The company serves the healthcare and pharmaceutical sectors.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Petros Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Petros Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →